Adage Capital Partners Gp, L.L.C. Tricida, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

  • $54.6 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$23.57 - $32.33 $10.8 Million - $14.9 Million
-460,000 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$22.5 - $39.35 $3.84 Million - $6.72 Million
-170,751 Reduced 27.07%
460,000 $14.1 Million
Q2 2018

Aug 14, 2018
BUY
$26.0 - $29.9 $16.4 Million - $18.9 Million
630,751 New
630,751 $18.9 Million

Others Institutions Holding TCDA

# of Institutions
4
Shares Held
30K
Call Options Held
124K
Put Options Held
46.5K
View Full List

About Tricida, Inc.

TCDA Quotes by TradingView
  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email